We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Control group

18 Oct 2021 By Jonathan Guilford

The biotech target’s 7% shareholder, Avoro Capital, is among funds that reckon the roughly $11 billion price Merck is offering is not high enough. There are arguments on both sides. But knocking the deal off course will be tough, especially as other bidders didn’t emerge.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)